Clinical Trial Update: Dose-finding Study of SPK-8016 Gene Therapy in Patients With Hemophilia A to Support Evaluation in Individuals With FVIII Inhibitors [Phase 1, Phase 2]

View source ↗

Summary

A dose-finding study of SPK-8016 gene therapy in Hemophilia A has completed Phase 1/2 testing to support evaluation in patients with FVIII inhibitors; results h…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemophilia

Drugs mentioned

• SPK-8016 (SPK-8016)

Snippet

Sponsor: Spark Therapeutics, Inc. | Conditions: Adeno-Associated Virus (AAV), Blood Coagulation Disorder | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2024-02-23